355 related articles for article (PubMed ID: 32018062)
1. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
[TBL] [Abstract][Full Text] [Related]
2. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.
Kurtzberg J; Prockop S; Chaudhury S; Horn B; Nemecek E; Prasad V; Satwani P; Teira P; Hayes J; Burke E;
Biol Blood Marrow Transplant; 2020 May; 26(5):855-864. PubMed ID: 32044400
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ
Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Steroid-Refractory Acute Graft-
Murata M; Teshima T
Front Immunol; 2021; 12():724380. PubMed ID: 34489977
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
7. Remestemcel-L for the treatment of graft versus host disease.
Locatelli F; Algeri M; Trevisan V; Bertaina A
Expert Rev Clin Immunol; 2017 Jan; 13(1):43-56. PubMed ID: 27399600
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons.
Tremblay G; Tomaras D; Strati E; Forsythe A
J Health Econ Outcomes Res; 2021 Feb; 8(1):10-17. PubMed ID: 33768123
[No Abstract] [Full Text] [Related]
10. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial.
Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q
J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J
Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
15. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
16. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
[TBL] [Abstract][Full Text] [Related]
17. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Yang D; Hou X; Qian K; Li Y; Hu L; Li L; Han M; Yao C; Liu D
Trials; 2023 May; 24(1):306. PubMed ID: 37138332
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.
Macías-Sánchez MDM; Morata-Tarifa C; Cuende N; Cardesa-Gil A; Cuesta-Casas MÁ; Pascual-Cascon MJ; Pascual A; Martín-Calvo C; Jurado M; Perez-Simón JA; Espigado I; Garzón López S; Carmona Sánchez G; Mata-Alcázar-Caballero R; Sánchez-Pernaute R
Stem Cells Transl Med; 2022 Apr; 11(4):343-355. PubMed ID: 35348788
[TBL] [Abstract][Full Text] [Related]
20. Extended Treatment With Mesenchymal Stromal Cells-Frankfurt am Main in a Pediatric Patient With Steroid-refractory Acute Gastrointestinal Graft-Versus-Host Disease: Case Report and Review of the Literature.
Gruhn B; Brodt G; Ernst J
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e419-e425. PubMed ID: 32118816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
